Lysine-plasminogen (Lys-PLG), the plasmin-modified form of native glutamic acid-plasminogen (Glu-PLG), displays enhanced binding affinity for fibrin and also enhanced activation by urokinase and tissue plasminogen activator. We previously demonstrated high-affinity, specific, and functional binding of
Introduction
Lysine-plasminogen (Lys-PLG)' is the 85,000-kD plasminmodified form of native, circulating glutamic acid-plasminogen (Glu-PLG). Plasmin cleaves the Lys 76-Lys 77 bond resulting in the release of a 76-amino acid "preactivation peptide" and formation of Lys-PLG (1) (2) (3) . Although it does not circulate in the plasma (4), Lys-PLG displays enhanced binding affinity for fibrin (5) , and is activated more readily than Glu-PLG by both tissue plasminogen activator (6) and uroki-nase (7, 8) . In the presence of tissue plasminogen activator, Lys-PLG is activated with 10 to 20 times greater catalytic efficiency (k,.jKm) than Glu-PLG (6) . This increase in activatability reflects a decrease in the Km of the reaction with little corresponding change in the catalytic rate constant (k,) (6) .
We have previously demonstrated that native Glu-PLG (9) , and its activators (10) , bind with high specificity and affinity to the surface ofcultured human umbilical vein endothelial cells (HUVEC). Binding of Glu-PLG, which was dose dependent, saturable, reversible, and lysine binding site dependent, resulted in a 12-fold increase in zymogen activatability on the cell surface due to a log-order decrease in the Km of the activation reaction (9) . We therefore examined whether this increase in catalytic efficiency at the endothelial cell surface might reflect the formation ofa more efficiently activated plasminogen species.
In this report we demonstrate dose-dependent, and lysinebinding site-dependent interaction of authentic Lys-PLG to two saturable binding sites on cultured HUVEC. Unlabeled Lys-PLG was a more effective competitor of 1251-Lys-PLG binding than unlabeled Glu-PLG, whereas either one competed effectively with '251-Glu-PLG for cell surface binding sites. Upon association with cultured HUVEC or endothelial cells in situ, _251-Glu-PLG was partially converted to a species which comigrated with '25I-Lys-PLG, through a reaction which was completely inhibited by the serine protease inhibitor diisopropylfluorophosphate (DFP) . Lys-PLG cross-reactive material was also detected by immunoblot analysis of eluates of intact umbilical cord veins, and by immunohistochemical staining of vascular endothelium in a variety of tissues. Therefore, Lys-PLG may represent a form unique to the cell surface, and endothelial cell-mediated conversion of Glu-PLG to Lys-PLG may contribute to the nonthrombogenic nature of the endothelium. Methods Materials. 96-(Falcon Labware, Oxnard, CA) and 24-(Costar, Cam- bridge, MA) well tissue culture plates were employed. L-Glutamine, penicillin-streptomycin, fungizone, porcine intestinal mucosal heparin, BSA (essentially fatty acid-and globulin-free), lactoperoxidase, tissue culture grade EDTA, DFP, phenylmethylsulfonyl fluoride, leu-Radioisotope labeling and radioligand binding studies. Purified human Glu-PLG and Lys-PLG were radiolabeled by the lactoperoxidase method (11) as previously described (9) . Radioligand binding studies with '251I-Lys-PLG were carried exactly as described for 125i-Glu-PLG (9), and analyzed according to the LIGAND computer program (12) .
SDS-PAGE. Samples were dissolved in 5% SDS, 50 mM Tris, 5 mM EDTA, 25% sucrose (wt/vol), and 50 Ag/ml bromphenol blue.
Samples were applied to 7.5% or 9.0% Laemmli (13) HUVEC, radioligand studies were performed (Fig. 3) . '25I-Lys-PLG, in a manner similar to the unlabeled ligand, interacted with HUVEC in a dose-dependent manner (Fig. 3 A) . Binding approached saturation at total ligand concentrations of 1.7-2.4 1M. Scatchard analysis of the data (Fig. 3 B) 20-fold molar excess for Glu-PLG as previously reported (9), suggesting a higher affinity of the relevant binding site for Lys-PLG. These results suggest that Lys-PLG may be the preferred ligand for at least a proportion of plasminogen binding sites on HUVEC.
Endothelial cell surface-mediated conversion ofGlu-PLG to Lys-PLG. When HUVEC in monolayer or suspension were incubated with authentic '25I-Glu-PLG, a new, more rapidly migrating molecular species of -87,000 kD was detected by electrophoresis in 7.5 or 9.0% nonreducing SDS Laemmli gels followed by autoradiography (Fig. 5) . In a previous study (9), we reported that '25I-Glu-PLG, upon binding to HUVEC, was recoverable in a form which comigrated with the input material. However, the SDS-PAGE system employed in those earlier experiments (3.5-17% Fairbanks system under reducing conditions) did not separate Glu-and Lys-forms. The new protein detected in the current study comigrated with authentic I25-Lys-PLG (lanes 1, 3, and 4) , and also reacted with a Lys-PLG-specific monoclonal antibody (LPm1) (4) ofthe new band was relatively temperature dependent. In time course studies performed at 40C or at 370C, the lower molecular mass species appeared within 10 min, plateaued at -30 min, and persisted for up to 4 h (data not shown). Neither empty wells, nor wells coated with postculture medium produced the same effect when incubated with the ligand, demonstrating that the reaction was not due to a soluble substance in the medium or contaminant on the well. Regardless of whether cells were studied in monolayer or in suspension, the appearance of a new 87,000-kD species was consistently noted, thus ruling out a major contribution by subendothelial matrix, and implicating the cell surface. In addition, as shown in Fig. 5 (lanes 5 and 6) , 95% of both molecular species could be eluted from the HUVEC surface with incubation buffer containing 10 mM EACA. This indicated that the bulk of the ligand was not internalized during the time frame of the experiment, and that the cell-ligand interaction was lysine-binding site dependent (Fig. 5) .
To determine whether binding of Glu-PLG to endothelial cells in situ could also be associated with conversion to a Lys-PLG-like species, umbilical vein perfusion experiments were carried out (Fig. 6) . Veins of intact, fresh umbilical cords were cannulated, washed to remove plasma proteins, and incubated with authentic '25I-Glu-PLG, form 1. The eluates were then collected, and the vessels washed to remove residual protein.
In a final step, the vessels were eluted with an EACA-containing buffer. Samples were run on SDS gels and autoradiographed. While the final wash material contained only Glu- Since the serine protease plasmin is the major enzyme known to convert Glu-PLG to Lys-PLG (1-3) , we examined the effect of various plasmin inhibitors on the ability of HUVEC to carry out this reaction. HUVEC, either in monolayer ( Fig. 7 A and C) or in suspension (Fig. 7 B) , were incubated with 125I-Glu-PLG in the presence or absence ofa variety of inhibitors. As shown in Fig. 7 A, a variety of protease inhibitors including PAI (lane 3), the rapidly acting physiologic inhibitor of both urokinase-like and tissue-type plasminogen activators, a2-PI (lane 6), and the general serine protease inhibitors pancreatic trypsin inhibitor (lane 4) and i-phenylalanyl-L-prolyl-L-arginine chloromethylketone (PPACK) (lane 5), all failed to impede the formation of the lower molecular weight species (lane 7). In data not shown, phenylmethylsulfonyl fluoride also failed to inhibit this effect. Only DFP (2.5 mM) (Fig. 7 C) In controlling specialized cellular functions, calcium-activated proteases may be plasma membrane associated (17) . We therefore tested "calpain" inhibitors in the same experiment (Fig. 7 B) . Neither leupeptin (lane 3) nor iodoacetic acid (lane 4) demonstrated any effect on the appearance of the lower molecular mass form, demonstrating that sulfhydryl proteases were most likely not involved in the Glu-PLG to Lys-PLG conversion.
Identification of Lys-PLG on endothelial surface of intact blood vessels. Immunoblot analysis was utilized to identify forms of plasminogen elutable with EACA from intact human umbilical veins. As demonstrated in Fig. 8 In addition, frozen sections of intact vessels from a variety of human tissues were evaluated immunohistochemically. Lys-PLG was detected on the surface of histologically normal human umbilical vein using the monoclonal antibody LPm 1 (Fig. 9 A) . The staining was localized to a rim on the endothelial cell surface. Similar but less intense staining was observed 1 2 3 4 on the endothelial cell surface of umbilical arteries. No staining was detected when the primary antibodies used were monoclonals to human X light chains, human prothrombin, or human albumin (not shown), or when monoclonal antibody LPm 1 was omitted (Fig. 9 B) . Similar specific staining for Lys-PLG was detected in vessels in other tissues including renal glomeruli during rejection, inflamed tonsil, dermal capillaries from patients with active systemic lupus erythematosus, and normal brain (Fig. 10 A-D) , as well as other tissues. These results suggest that Lys-PLG may be a widespread component of the endothelial surface. Without benefit of a monoclonal antibody specific for Glu-PLG, it was impossible to determine whether this protein had a similar distribution on the endothelium. Results from polyclonal blotting experiments referred to above suggest that Glu-PLG may represent 15-29% of total elutable plasminogen on normal umbilical veins.
Discussion
This study demonstrates for the first time that the human endothelial cell surface has the capacity to convert the circulating, native form of plasminogen (Glu-PLG) to its modified, more activatable form (Lys-PLG). In addition, we have shown that cultured HUVEC can bind Lys-PLG with high affinity and in a saturable, reversible, and lysine-binding site-dependent fashion, and that Lys-PLG is a preferred ligand for a proportion of plasminogen-binding sites on the cell surface. Lys-PLG has also been demonstrated on the surface of endothelial cells in tissue sections stained with a specific monoclonal antibody (LPm 1), and Lys-PLG was also recovered in EACA eluates from intact umbilical vessels. Thus, whereas Glu-PLG circulates in the plasma, Lys-PLG may represent a specialized, "preactivation" form of this zymogen which is confined to cell surfaces.
Historically, the role of preactivation intermediates in plasminogen activation has been controversial. Based on electrophoretic and circular dichroism analyses of activation of Glu-PLG in vitro, it was originally proposed that activation in vivo might involve the formation ofN-terminal lysyl or methionyl forms of the molecule (1, 18, 19) . More recently, however, with the availability of a Lys-PLG specific monoclonal antibody, neither Lys-PLG nor Lys-plasmin-antiplasmin complexes could be detected in the plasma of normal subjects, although three ofseven patients undergoing thrombolytic therapy with tissue plasminogen activator had circulating Lysplasmin-antiplasmin (4). Our data suggest that formation of the preactivation intermediate Lys-PLG may be physiologic in a compartment confined to the vessel wall, and we hypothesize that an endothelial cell serine protease may mediate this event.
Previous studies have shown that human Glu-PLG, the native, circulating form, binds specifically and with high affinity to cultured HUVEC (9), at a site possibly related to cellsurface gangliosides (20). The present study now indicates by both ELISA (Fig. 1) and radioligand experiments (Fig. 3) for Scatchard analysis, which demonstrated the presence of two discrete saturable sites. The present data indicate, furthermore, that Lys-PLG may represent a preferred ligand for a proportion of plasminogen binding sites on the cell surface. In cold competition studies, Lys-PLG proved to be a far better competitor of '251I-Lys-PLG binding than Glu-PLG (Fig. 4 A) . The I50 for Glu-PLG (48-fold excess) was -1/2 log orders higher than that for Lys-PLG (equimolar), suggesting much higher affinity of these sites for Lys-PLG as opposed to Glu-PLG. Lys-PLG was also at least as effective a competitor as Glu-PLG for 125I-Glu-PLG binding sites with 150 values suggesting a higher affinity for these sites (Fig. 4 B) . Formal binding data (Fig. 3) corroborate this finding since the dissociation constant for the major Lys-PLG site (120 nM) is two-to threefold lower than that previously determined for Glu-PLG (310 nM) (9) .
Our studies clearly demonstrate that cultured endothelial cells (Fig. 5 ) and endothelial cells in situ (Fig. 6) have the capacity to convert Glu-PLG to Lys-PLG. This effect was rapid and temperature dependent, suggesting a discrete catalytic event. Since the formation of Lys-PLG from Glu-PLG could be inhibited by the serine protease inhibitor DFP, we have postulated that this reaction is carried out by a serine protease with Lys-Lys specificity. Although plasmin remains a possible contender, we have been unable to inhibit the conversion with several agents known to inhibit fluid phase plasmin, including a2-PI, PPACK, and leupeptin (Fig. 7) . Although plasmin associated with group A streptococci was insensitive to a2-PI, it was inhibited by aprotinin or PPACK (21). Similar active site protection from physiologic inhibitors has also been reported for sperm-associated ram seminal acrosin (22) , macrophage-associated urokinase (23, 24) , fibrin-associated plasmin (25) , and HUVEC-bound tissue plasminogen activator (10), thus raising the question ofwhether a protected form of plasmin could be the catalytic agent.
Cell surface binding sites for fibrinolytic proteins are ubiquitous in nature (26, 27) . Urokinase is found in association with fibroblasts (28, 29) , the monocytoid cell line U937 (30, 31) , the epidermoid cell line A431 (32, 33) , mouse spermatozoa (34) , and mouse erythroleukemia cells (35) . Tissue plasminogen activator binds to HUVEC (10) , and plasmin has been reported to bind to cultured mini-pig aortic endothelial cells (36) , and has also been found by immunofluorescence on various tumor cells (37, 38) . Glu-PLG interacts with platelets (39, 40) , U937 cells and fibroblasts (41) , and monocytes, granulocytes, and lymphocytes, but not erythrocytes (42) . Plasminogen has also been found by immunofluorescence in association with capillary endothelium (37 1 and 2) and which reacts with a monoclonal antibody (LPm 1) specific for Lys-PLG (Fig. 8) . Similar experiments with polyclonal antibody showed a third cross-reacting band that comigrated with Glu-PLG, suggesting that a small per- 
